Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... therapy (IST) or IST and eltrombopag, and 10 IST- refractory patients who had received eltrombopag only, focusing on ...

    Research Article last updated 10/23/2017 - 11:19am.

  2. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... responses are often short-lived. In fact, many ESA- refractory patients harbor defects in late-stage erythropoiesis downstream ...

    Research Article last updated 10/23/2017 - 11:08am.

  3. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... constitute the "previously treated" and "relapsed/ refractory " MDS populations, and how specifically to define disease ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

    ... Early failure to ESA and a baseline diagnosis of refractory anemia with excess blasts (RAEB)-1 were ...

    Research Article last updated 03/05/2013 - 9:29am.

  5. Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA)

    ... in patients 60 years of age or older with relapsed or refractory AML who are ineligible for standard intensive chemotherapy ... In the Selinexor in Older Patient with Relapsed/Refractory AML (SOPRA) study, Karyopharm is evaluating approximately 170 ...

    Clinical Trial last updated 08/26/2016 - 9:21am.

  6. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and ... subjects with high-risk MDS/CMML who have relapsed or are refractory to prior therapy; Cohort 2 will include subjects with AML who have ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  7. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... responses are often short-lived. In fact, many ESA- refractory patients harbor defects in late-stage erythropoiesis downstream ...

    Research Article last updated 10/02/2017 - 10:10am.

  8. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... therapy (IST) or IST and eltrombopag; 10 IST- refractory patients who had received eltrombopag only), focusing on ...

    Research Article last updated 10/02/2017 - 9:40am.

  9. Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug

    ... efficacious in a subset of patients with aplastic anemia refractory to IST, with frequent multilineage responses, and maintenance of ...

    Research Article last updated 01/07/2014 - 12:22pm.

  10. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

    ... IST regimens in frontline and relapsed/ refractory (R/R) settings. Pretreatment and on-treatment clinical ... prior response to ATG: prior responders (46%) vs primary refractory (0%) (p<0.01). In the R/R setting, there was no survival difference ...

    Research Article last updated 09/13/2017 - 7:40am.